824 related articles for article (PubMed ID: 28698093)
1. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases.
Li Y; Tang R; Leung PSC; Gershwin ME; Ma X
Autoimmun Rev; 2017 Sep; 16(9):885-896. PubMed ID: 28698093
[TBL] [Abstract][Full Text] [Related]
2. The gut microbial influence on cholestatic liver disease.
Kummen M; Hov JR
Liver Int; 2019 Jul; 39(7):1186-1196. PubMed ID: 31125502
[TBL] [Abstract][Full Text] [Related]
3. Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC).
Mattner J
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834858
[TBL] [Abstract][Full Text] [Related]
4. The Gut-Liver Axis in Cholestatic Liver Diseases.
Blesl A; Stadlbauer V
Nutrients; 2021 Mar; 13(3):. PubMed ID: 33801133
[TBL] [Abstract][Full Text] [Related]
5. Exploring Advanced Therapies for Primary Biliary Cholangitis: Insights from the Gut Microbiota-Bile Acid-Immunity Network.
Guo Z; He K; Pang K; Yang D; Lyu C; Xu H; Wu D
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673905
[TBL] [Abstract][Full Text] [Related]
6. [The intestinal microflora and cholestatic liver diseases].
Zhu L; Xing HC
Zhonghua Gan Zang Bing Za Zhi; 2019 May; 27(5):325-329. PubMed ID: 31177655
[TBL] [Abstract][Full Text] [Related]
7. Gut microbiome in primary sclerosing cholangitis: A review.
Little R; Wine E; Kamath BM; Griffiths AM; Ricciuto A
World J Gastroenterol; 2020 Jun; 26(21):2768-2780. PubMed ID: 32550753
[TBL] [Abstract][Full Text] [Related]
8. Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic γδ T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Tedesco D; Thapa M; Chin CY; Ge Y; Gong M; Li J; Gumber S; Speck P; Elrod EJ; Burd EM; Kitchens WH; Magliocca JF; Adams AB; Weiss DS; Mohamadzadeh M; Grakoui A
Gastroenterology; 2018 Jun; 154(8):2178-2193. PubMed ID: 29454797
[TBL] [Abstract][Full Text] [Related]
9. Metabolomic analysis of cholestatic liver damage in mice.
Yang R; Zhao Q; Hu DD; Xiao XR; Huang JF; Li F
Food Chem Toxicol; 2018 Oct; 120():253-260. PubMed ID: 30009888
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between Gut Microbiota and Bile Acids in Cholestatic Liver Disease.
Shi Q; Yuan X; Zeng Y; Wang J; Zhang Y; Xue C; Li L
Nutrients; 2023 May; 15(10):. PubMed ID: 37242293
[TBL] [Abstract][Full Text] [Related]
11. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis.
Pollheimer MJ; Fickert P; Stieger B
Mol Aspects Med; 2014 Jun; 37():35-56. PubMed ID: 24141039
[TBL] [Abstract][Full Text] [Related]
12. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling.
Schneider KM; Candels LS; Hov JR; Myllys M; Hassan R; Schneider CV; Wahlström A; Mohs A; Zühlke S; Liao L; Elfers C; Kilic K; Henricsson M; Molinaro A; Hatting M; Zaza A; Drasdo D; Frissen M; Devlin AS; Gálvez EJC; Strowig T; Karlsen TH; Hengstler JG; Marschall HU; Ghallab A; Trautwein C
Nat Metab; 2021 Sep; 3(9):1228-1241. PubMed ID: 34552267
[TBL] [Abstract][Full Text] [Related]
13. [Cholestatic liver diseases].
Grimm D; Thimme R
Ther Umsch; 2011 Apr; 68(4):195-9. PubMed ID: 21452140
[TBL] [Abstract][Full Text] [Related]
14. Intestinal microbiota drives cholestasis-induced specific hepatic gene expression patterns.
Juanola O; Hassan M; Kumar P; Yilmaz B; Keller I; Simillion C; Engelmann C; Tacke F; Dufour JF; De Gottardi A; Moghadamrad S
Gut Microbes; 2021; 13(1):1-20. PubMed ID: 33847205
[TBL] [Abstract][Full Text] [Related]
15. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.
Liao L; Schneider KM; Galvez EJC; Frissen M; Marschall HU; Su H; Hatting M; Wahlström A; Haybaeck J; Puchas P; Mohs A; Peng J; Bergheim I; Nier A; Hennings J; Reißing J; Zimmermann HW; Longerich T; Strowig T; Liedtke C; Cubero FJ; Trautwein C
Gut; 2019 Aug; 68(8):1477-1492. PubMed ID: 30872395
[TBL] [Abstract][Full Text] [Related]
16. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Shah A; Macdonald GA; Morrison M; Holtmann G
Am J Gastroenterol; 2020 Jun; 115(6):814-822. PubMed ID: 32250997
[TBL] [Abstract][Full Text] [Related]
17. Role of intestinal flora in primary sclerosing cholangitis and its potential therapeutic value.
Li ZJ; Gou HZ; Zhang YL; Song XJ; Zhang L
World J Gastroenterol; 2022 Nov; 28(44):6213-6229. PubMed ID: 36504550
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota translocation promotes autoimmune cholangitis.
Ma HD; Zhao ZB; Ma WT; Liu QZ; Gao CY; Li L; Wang J; Tsuneyama K; Liu B; Zhang W; Zhou Y; Gershwin ME; Lian ZX
J Autoimmun; 2018 Dec; 95():47-57. PubMed ID: 30340822
[TBL] [Abstract][Full Text] [Related]
19. The ascending pathophysiology of cholestatic liver disease.
Jansen PL; Ghallab A; Vartak N; Reif R; Schaap FG; Hampe J; Hengstler JG
Hepatology; 2017 Feb; 65(2):722-738. PubMed ID: 27981592
[TBL] [Abstract][Full Text] [Related]
20. New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Williamson KD; Chapman RW
Semin Liver Dis; 2016 Feb; 36(1):5-14. PubMed ID: 26870928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
